INAB
IN8bio, Inc.NASDAQHealthcare$1.44+2.86%ClosedMarket Cap: $6.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.22
P/S
0.00
EV/EBITDA
1.02
DCF Value
$5.49
FCF Yield
-194.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-111.3%
ROA
-60.2%
ROIC
-64.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-5.0M | $-4.9M | $-0.51 | — |
| FY 2025 | $0.00 | -Infinity% | $-19.9M | $-19.4M | $-4.44 | — |
| Q3 2025 | $0.00 | NaN% | $-3.9M | $-3.9M | $-0.85 | — |
| Q2 2025 | $0.00 | NaN% | $-5.1M | $-5.1M | $-1.24 | — |
| Q1 2025 | $0.00 | NaN% | $-5.5M | $-5.5M | $-0.07 | — |
| Q4 2024 | $0.00 | NaN% | $-6.2M | $-6.2M | $-0.09 | — |
| FY 2024 | $0.00 | NaN% | $-30.4M | $-30.4M | $-0.57 | — |
| Q3 2024 | $0.00 | NaN% | $-7.1M | $-7.1M | $-0.15 | — |
| Q2 2024 | $0.00 | NaN% | $-8.6M | $-8.6M | $-0.19 | — |
| Q1 2024 | $0.00 | NaN% | $-8.6M | $-8.6M | $-0.20 | — |
| Q4 2023 | $0.00 | NaN% | $-7.9M | $-7.6M | $-0.21 | — |
| FY 2023 | $0.00 | -Infinity% | $-30.3M | $-30.0M | $-1.00 | — |